Figure 7.

FGFs enhance C2C12 cell proliferation.

Results of cell counting, MTT assay and CellTiter 96® AQueous One kit in C2C12 cells treated with FGF9 (2–50 ng/mL), FGF16 (100 ng/mL) and FGF20 (100 ng/mL). (a) With FGF9 treatment, compared to control, no significant difference of cell number was observed with 2 ng/mL at day 1. A significant increase in cell number was detected in the 2 ng/mL group at days 2 and 3. At days 1–3, in the 10 ng/mL and 50ng/mL groups a significant increase in cell number was observed (n = 3, *p< 0.05, **p< 0.01). (b) In the MTT assay, similar results were observed, except that no significant difference was noted with 2 ng/mL FGF9 at day 2 (n = 4, *p< 0.05, **p< 0.01). The effect of FGF16 and FGF20 on C2C12 myoblast proliferation was determined by cell counting and CellTiter 96® AQueous One kit. (c) In the cell counting assay, compared to control, FGF9 (10 ng/mL) (as positive control), FGF16 (100 ng/mL) and FGF20 (100 ng/mL) significantly increased the number of C2C12 cells. (d) Similar results were observed with CellTiter 96® AQueous One kit (n = 3, *p< 0.05, **p< 0.01).